182
L. Cai et al. / International Journal of Pharmaceutics 408 (2011) 173–182
References
Matsumura, Y., Kataoka, K., 2009. Preclinical and clinical studies of anticancer agent-
incorporating polymer micelles. Cancer Sci. 100, 572–579.
Moghimi, S.M., Hunter, A.C., Murray, J.C., 2001. Long-circulating and target-specific
nanoparticles: theory to practice. Pharmacol. Rev. 53, 283–318.
Bikram, M., Ahn, C., Chae, S.Y., Lee, M., Yockman, J.W., Kim, S.W., 2004. Biodegradable
poly (ethylene glycol)-co-poly (L-lysine)-g-histidine multiblock copolymers for
nonviral gene delivery. Macromolecules 37, 1903–1916.
Chen, X., Wang, X.H., Wang, Y.S., Yang, L., Hu, J., Xiao, W.J., Fu, A.F., Cai, L.L.,
Li, X., Ye, X., Liu, Y.L., Wu, W.S., Shao, X.M., Mao, Y.Q., Wei, Y.Q., Chen, L.J.,
2010. Improved tumor-targeting drug delivery and therapeutic efficacy by
cationic liposome modified with truncated bFGF peptide. J. Control. Release 145,
17–25.
Dharap, S.S., Wang, Y., Chandna, P., Khandare, J.J., Qiu, B., Gunaseelan, S., Sinko, P.J.,
Stein, S., Farmanfarmaian, A., Minko, T., 2005. Tumor-specific targeting of an
anticancer drug delivery system by LHRH peptide. Proc. Natl. Acad. Sci. U.S.A.
102, 12962–12967.
Goldman, C.K., Rogers, B.E., Douglas, J.T., Sosnowski, B.A., Ying, W.B., Siegal, G.P.,
1997. Targeted gene delivery to Kaposi’s sarcoma cells via the fibroblast growth
factor receptor. Cancer Res. 57, 1447–1451.
Nasongkla, N., Bey, E., Ren, J., Ai, H., Khemtong, C., Setti Guthi, J., Chin, S.F., Sherry,
A.D., Boothman, D.A., Gao, J., 2006. Multifunctional polymeric micelles as cancer-
targeted, MRI-ultrasensitive drug delivery systems. Nano Lett. 6, 2427–2430.
Nishiyama, N., Okazaki, S., Cabral, H., Miyamoto, M., Kato, Y., Sugiyama, Y., Nishio,
K., Matsumura, Y., Kataoka, K., 2003. Novel cisplatin-incorporated polymeric
micelles can eradicate solid tumors in mice. Cancer Res. 63, 8977–8983.
Otsuka, H., Nagasaki, Y., Kataoka, K., 2003. PEGylated nanoparticles for biological
and pharmaceutical applications. Adv. Drug Deliv. Rev. 5, 403–419.
Plum, S.M., Holaday, J.W., Ruiz, A., Madsen, J.W., Fogler, W.E., Fortier, A.H., 2000.
Administration of a liposomal FGF-2 peptide vaccine leads to abrogation of FGF-
2-mediated angiogenesis and tumor development. Vaccine 19, 1294–1303.
Rancourt, C., Rogers, B.E., Sosnowski, B.A., Wang, M.H., Piche, A., Pierce, G.F., 1998.
Basic fibroblast growth factor enhancement of adenovirus-mediated delivery of
the herpes simplex virus thymidine kinase gene results in augmented therapeu-
tic benefit in a murine model of ovarian cancer. Clin. Cancer Res. 4, 2455–2461.
Rosa, P.A.J., Azevedo, A.M., Ferreira, I.F., Vries, J.de, Korporaal, R., Verhoef, H.J., Visser,
T.J., 2007. J. Chromatogr. 1162, 103–113.
Shchors, K., Evan, G., 2007. Tumor angiogenesis: cause or consequence of cancer?
Cancer Res. 67, 7059–7061.
Shuai, X., Ai, H., Nasongkla, N., Kim, S., Gao, J., 2004. Micellar carriers based on
block copolymers of poly (epsilon-caprolactone) and poly (ethylene glycol) for
doxorubicin delivery. J. Control. Release 98, 415–426.
Sosnowski, B.A., Gonzalez, A.M., Chandler, L.A., Buechler, Y.J., Pierce, G.F., Baird, A.,
1996. Targeting DNA to cells with basic fibroblast growth factor (FGF2). J. Biol.
Chem. 271, 33647–33653.
Sutton, D., Nasongk, N., Blanco, E., Gao, J., 2007. Functionalized micellar systems for
cancer targeted drug delivery. Pharm. Res. 24, 1029–1046.
Terada, T., Mizobata, M., Kawakami, S., Yabe, Y., Yamashita, F., Hashida, M., 2006.
Basic fibroblast growth factor-binding peptide as a novel targeting ligand of
drug carrier to tumor cells. J. Drug Target 14, 536–545.
Terada, T., Mizobata, M., Kawakami, S., Yamashita, F., Hashida, M., 2007. Opti-
mization of tumor-selective targeting by basic fibroblast growth factor-binding
peptide grafted PEGylated liposomes. J. Control. Release 119, 262–270.
Toncheva, V., Schacht, E., Ng, S.Y., Barr, J., Heller, J., 2003. Use of block copolymers
of poly (ortho esters) and poly (ethylene glycol) micellar carriers as potential
tumour targeting systems. J. Drug Target. 11, 345–353.
Torchilin, V.P., 2001. Structure and design of polymeric surfactant-based drug deliv-
ery systems. J. Control. Release 73, 137–172.
Torchilin, P.V., Lukyanov, N.A., Gao, Z.G., Brigitte, P.S., 2003. Immunomicelles: Tar-
geted pharmaceutical carriers for poorly soluble drugs. Proc. Natl. Acad. Sci.
U.S.A. 100, 6039–6044.
Yamamoto, Y., Nagasaki, Y., Kato, Y., Sugiyama, Y., Kataoka, K., 2001. Long-circulating
poly (ethylene glycol)-poly (D, L-lactide) block copolymer micelles with modu-
lated surface charge. J. Control. Release 77, 27–38.
Zamboni, W.C., 2005. Liposomal, nanoparticle, and conjugated formulations of anti-
cancer agents. Clin. Cancer Res. 11, 8230–8234.
Zelphati, O., Wang, Y., Kitada, S., Reed, J.C., Felgner, P.L., Corbeil, J., 2001. Intracellular
delivery of proteins with a new lipid-mediated delivery system. J. Biol. Chem.
276, 35103–35110.
Hamaguchi, T., Matsumura, Y., Suzuki, M., Shimizu, K., Goda, R., Nakamura,
I., Nakatomi, I., Yokoyama, M., Kataoka, K., Kakizoe, T., 2005. NK105,
a
paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo
antitumour activity and reduce the neurotoxicity of paclitaxel. Br. J. Cancer 92,
1240–1246.
Harashima, H., Ishida, T., Kamiya, H., Kiwada, H., 2002. Pharmacokinetics of targeting
with liposomes. Crit. Rev. Ther. Drug Carrier Syst. 9, 235–275.
He, Q.M., Wei, Y.Q., Tian, L., Zhao, X., Su, J.M., Yang, L., Lu, Y., Kan, B., Lou, Y.Y., Huang,
M.J., Xiao, F., Liu, J.Y., Hu, B., Luo, F., Jiang, Y., Wen, Y.j., Deng, H.X., Li, J., Niu,
T., Yang, J.L., 2003. Inhibition of tumor growth with a vaccine based on xeno-
geneic homologous fibroblast growth factor receptor-1 in mice. Biol. Chem. 278,
21831–21836.
Kerbel, R.S., 2000. Tumor angiogenesis: past, present and the near future. Carcino-
genesis 21, 505–515.
Kim, T.Y., Kim, D.W., Chung, J.Y., Shin, S.G., Kim, S.C., Heo, D.S., Heo, N.K., Bang,
Y.J., 2004. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free,
polymeric micelle-formulated paclitaxel, in patients with advanced malignan-
cies. Clin. Cancer Res. 10, 3708–3716.
Kong, H.L., Crystal, R.G., 1998. Gene therapy strategies for tumor antiangiogenesis.
J. Natl. Cancer Inst. 90, 273–286.
Kwon, G.S., 2003. Polymeric micelles for delivery of poorly water-soluble com-
pounds. Crit. Rev. Ther. Drug Carrier Syst. 20, 357–403.
Lasic, D.D., 1992. Mixed micelles in drug delivery. Nature 355, 279–280.
Lee, H., Hu, M., Reilly, R.M., Allen, C., 2007. Apoptotic epidermal growth factor (EGF)-
conjugated block copolymer micelles as a nanotechnology platform for targeted
combination therapy. Mol. Pharm. 4, 769–781.
Li, D., Yu, H., Huang, H.L., Shen, F.P., Wu, X.Y., Li, J.Z., 2007. FGF receptor-mediated
gene delivery using ligands coupled to Polyethylenimine. Biomater. Appl. 22,
163–180.
Liu, L.H., Guo, K., Lu, J., Venkatraman, S.S., Luo, D., Ng, K.C., Ling, E.A., Moochhala,
S., Yang, Y.Y., 2008. Biologically active core/shell nanoparticles self-assembled
from cholesterol-terminated PEG-TAT for drug delivery across the blood brain
barrier. Biomaterials 29, 1509–1517.
Matsumura, Y., Hamaguchi, T., Ura, T., Muro, K., Yamada, Y., Shimada, Y., Shirao, K.,
Okusaka, T., Ueno, H., Ikeda, M., Watanabe, N., 2004. Phase I clinical trial and
pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. Br.
J. Cancer 91, 1775–1811.